GT200500267A - Uso de epotilonas en el tratamiento de metastasis en hueso - Google Patents

Uso de epotilonas en el tratamiento de metastasis en hueso

Info

Publication number
GT200500267A
GT200500267A GT200500267A GT200500267A GT200500267A GT 200500267 A GT200500267 A GT 200500267A GT 200500267 A GT200500267 A GT 200500267A GT 200500267 A GT200500267 A GT 200500267A GT 200500267 A GT200500267 A GT 200500267A
Authority
GT
Guatemala
Prior art keywords
epotilones
treatment
bone metastasis
metastasis
bone
Prior art date
Application number
GT200500267A
Other languages
English (en)
Inventor
Jens Hoffmann
Ulrich Klar
Hubertus Pietsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200500267(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200500267A publication Critical patent/GT200500267A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE AL USO DE UNA EPOTILONA PARA LA PREPARACION DE UN MEDICAMENTO PARA UTILIZAR CO-
GT200500267A 2004-09-24 2005-09-23 Uso de epotilonas en el tratamiento de metastasis en hueso GT200500267A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04090377A EP1640004A1 (en) 2004-09-24 2004-09-24 Use of epothilones in the treatment of bone metastases and bone tumors or cancers

Publications (1)

Publication Number Publication Date
GT200500267A true GT200500267A (es) 2006-06-06

Family

ID=34928830

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500267A GT200500267A (es) 2004-09-24 2005-09-23 Uso de epotilonas en el tratamiento de metastasis en hueso

Country Status (21)

Country Link
EP (2) EP1640004A1 (es)
JP (1) JP2008514569A (es)
KR (1) KR20070054214A (es)
CN (1) CN101065126A (es)
AR (1) AR051035A1 (es)
AU (1) AU2005287477A1 (es)
BR (1) BRPI0516080A (es)
CA (1) CA2580215A1 (es)
CR (1) CR9064A (es)
EC (1) ECSP077390A (es)
GT (1) GT200500267A (es)
IL (1) IL181785A0 (es)
MX (1) MX2007003503A (es)
NO (1) NO20072099L (es)
PA (1) PA8646201A1 (es)
PE (1) PE20060695A1 (es)
RU (1) RU2007115162A (es)
TW (1) TW200626150A (es)
UY (1) UY29136A1 (es)
WO (1) WO2006032537A2 (es)
ZA (1) ZA200703306B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1930004A1 (en) * 2006-12-08 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Use of epothilones in the treatment of osteoporosis and related diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
CA2352505C (en) * 1998-12-22 2009-04-07 Novartis Ag Epothilone derivatives and their use as antitumor agents
AR023792A1 (es) * 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
WO2001024763A2 (en) * 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
JP2004508810A (ja) * 2000-04-28 2004-03-25 コーサン　バイオサイエンシーズ，　インコーポレイテッド ポリケチドの生成
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
WO2002080846A2 (en) * 2001-04-03 2002-10-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
AU2003218107A1 (en) * 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
WO2003092683A1 (en) * 2002-05-01 2003-11-13 Novartis Ag Epothilone derivative for the treatment of hepatoma and other cancer diseases
AU2003294796A1 (en) * 2002-12-05 2004-06-23 Schering Ag Epothilone analogs for site specific delivery in the treatment of proliferative diseases
GB0305928D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
EP1475105A1 (en) * 2003-05-09 2004-11-10 Schering AG Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy
MXPA05013958A (es) * 2003-06-27 2006-02-24 Novartis Ag Tratamiento de cancer con epotilona.
CN1870995A (zh) * 2003-09-02 2006-11-29 诺瓦提斯公司 使用埃坡霉素的癌症治疗

Also Published As

Publication number Publication date
CR9064A (es) 2007-10-01
ECSP077390A (es) 2007-05-30
BRPI0516080A (pt) 2008-08-19
WO2006032537A3 (en) 2006-05-04
KR20070054214A (ko) 2007-05-28
TW200626150A (en) 2006-08-01
IL181785A0 (en) 2007-07-04
RU2007115162A (ru) 2008-11-20
CA2580215A1 (en) 2006-03-30
PA8646201A1 (es) 2006-11-09
AU2005287477A1 (en) 2006-03-30
AR051035A1 (es) 2006-12-13
MX2007003503A (es) 2007-08-17
EP1809281A2 (en) 2007-07-25
WO2006032537A2 (en) 2006-03-30
NO20072099L (no) 2007-04-23
PE20060695A1 (es) 2006-08-03
EP1640004A1 (en) 2006-03-29
JP2008514569A (ja) 2008-05-08
CN101065126A (zh) 2007-10-31
ZA200703306B (en) 2010-06-30
UY29136A1 (es) 2006-04-28

Similar Documents

Publication Publication Date Title
CY1116435T1 (el) Ενωσεις βορονικου εστερα και φαρμακευτικες συνθεσεις αυτων
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
DOP2006000082A (es) Forma cristalina ortorrómbicadel maleato de asenapina y su uso enel tratamiento de trastornos mentales.
PH12014500053A1 (en) Proteasome inhibitors
UY31484A1 (es) Piperidinas heteroaril-sustituidas
ECSP10010295A (es) Formulacion de anticuerpo
BRPI0608297A2 (pt) composições de lipossomos
BRPI0618239A8 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
UY30333A1 (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
HN2006037713A (es) Compuestos utiles en terapia
HN2002000266A (es) Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad.
SV2009003098A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
GT200500363A (es) 3-amino-pirazol [3,4b] piridinas con inhibidores de proteintirosinquinasas, su preparacion y uso como medicamento.
TNSN08381A1 (en) Cosmetic active ingredient composed of arginine ferrulate and a microalgae and extract its uses
HN2006029142A (es) Proceso
UY32052A (es) 5-aminopirazoles sustituidos y uso de los mismos
HN2003000379A (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes
GT200500031A (es) Procesos para la preparacion de haluros de arilalquilsulfonilo y haluros de heteroarilalquilsulfonilo
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.
UY31758A (es) Forma cristalina anhidra de maleato de orvepitant
UY29817A1 (es) Nuevos compuestos de azetidina, composiciones farmacéuticas que los contienen, procesos de preparación y uso terapéutico de los mismos.
SV2010003753A (es) Dronedarona para la prevencion de la cardioversion
SV2010003773A (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.